44
Participants
Start Date
December 14, 2017
Primary Completion Date
October 31, 2018
Study Completion Date
December 23, 2020
Pembrolizumab
MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
Eribulin
Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
Corporació Sanitaria Sanitari Parc Taulí, Sabadell
Hospital de Navarra, Pamplona
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
Hospital Clínic de Barcelona, Barcelona
Instituto Oncológico Baselga - Hospital Quirónsalud Barcelona, Barcelona
Hospital Universitario Ramón y Cajal, Madrid
MD Anderson, Madrid
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia
Hospital Universitario Virgen del Rocío, Seville
Hospital Arnau de Vilanova de Valencia, Valencia
Hospital Clínico de Valencia, Valencia
MedSIR
OTHER